No Data
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
Xuantai Medicine (688247.SH) released its performance for the first half of the year, with a net income of 54.1533 million yuan, a year-on-year increase of 137.6%.
Xuantai Pharmaceutical (688247.SH) released its 2024 interim report, with revenue of 0.218 billion yuan for the company...
Xuantai Pharmaceuticals (688247.SH): Net income in the first half of the year was 54.1533 million yuan, a year-on-year increase of 137.6%.
On August 30th, Gelonghui announced its semi-annual report. During the reporting period, the company achieved a revenue of 217.9946 million yuan, a year-on-year increase of 96.81%; the net profit attributable to the owners of the parent company was 54.1533 million yuan, a year-on-year increase of 137.60%; the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses was 48.7934 million yuan, a year-on-year increase of 167.97%. The company plans to distribute a cash dividend of 0.25 yuan per 10 shares to all shareholders.
Xuantai Pharmaceuticals (688247.SH): 2.267 million restricted shares will be lifted on August 26th.
On August 16, Gelon Hui announced that the total number of shares publicly listed by Xuantai Pharmaceuticals (688247.SH) this time is 2.267 million. The date of stock listing is August 26, 2024 (August 25, 2024 is a non-trading day, and the listing date is postponed to August 26, 2024).
Xuantai Medicine (688247.SH): Has not developed class 1 new drugs, currently providing preparation CRO/CMO services to domestic and foreign new drug companies and research institutions.
On July 19th, Gelunhui reported that an investor asked Xuantai Pharmaceutical (688247.SH) on the investor interactive platform whether the company is also developing innovative drugs. The company replied that it has not developed Category 1 new drugs. Currently, the company provides formulation CRO/CMO services to domestic and foreign new drug companies and research institutions. Previously, Xuantai Pharmaceuticals was awarded the "Top Ten Drug Innovation Service Institutions of the Year" at the fourth Securities Times Drug Innovation and Public Welfare Awards for its outstanding performance in many areas.
No Data
